Latest news with #IPF
CTV News
3 days ago
- Sport
- CTV News
North Bay powerlifter sets world record, wins international gold
North Bay's Tihanna Draves set a world record and won gold in women's 84kg classic at the 2025 IPF World University Powerlifting Cup in Istanbul. A 24-year-old powerlifting athlete from North Bay, Ont., made history at the 2025 International Powerlifting Federation World University Powerlifting Cup in Istanbul, Turkey, securing a gold medal and setting a new world record in the Women's 84 kg Classic division. Tihanna Draves, representing Swansea University, dominated the competition with a total lift of 461.5 kg, comprising a 185.5 kg squat, 98.5 kg bench press and 177.5 kg deadlift. Her performance not only earned her the top podium spot but also established a new world record for the university-level event. Tihanna Draves Tihanna Draves, 24, of North Bay, Ont., tops the podium at the International Powerlifting Federation World University Powerlifting Cup in Istanbul, Turkey, in July 2025. (Supplied/Tihanna Draves) Draves narrowly edged out silver medalist Kerry Wood of the University of Nottingham by a mere 3 kg. A surprising triumph in her international debut Reflecting on her victory, Draves admitted she hadn't anticipated such a breakthrough. 'I didn't know it was happening. I knew that I was probably going to beat a few records, but I wasn't too sure,' she said. 'It was my first international meet. So, I was just trying to stay calm and stay collected.' The World University Cup, organized by the International Powerlifting Federation (IPF), brings together elite student-athletes to compete in classic (raw) powerlifting. As the sport's global governing body, the IPF oversees international championships, ratifies world records and promotes drug-free competition across all age groups. Tihanna Draves Tihanna Draves of North Bay, Ont., wins gold at the International Powerlifting Federation World University Powerlifting Cup in Istanbul, Turkey, in July 2025. (Supplied/Tihanna Draves | Image credit: International Powerlifting Federation) From gymnastics to powerlifting stardom Draves, who grew up in North Bay, has long been drawn to individual sports, initially excelling in gymnastics before discovering powerlifting just a year and a half ago while studying at Swansea University in Wales. Starting university later than most of her peers, she sought a new outlet for personal growth. 'I was introduced to my coach Will, and I think he kind of realized like, 'Oh. She might not be bad at this,'' she said. 'So, I started getting coached while following a program. Then I competed a few times and then got invited to represent GB (Great Britain).' Her rapid rise in the sport has been remarkable. Earlier this year, she achieved personal bests at the British Universities and Colleges Sport Powerlifting Championships in the UK, setting the stage for her record-breaking performance in Istanbul. Ambitions for the future Tihanna Draves Tihanna Draves of North Bay, Ont., competes and sets a world record at the International Powerlifting Federation World University Powerlifting Cup in Istanbul, Turkey, in July 2025. (Supplied/Tihanna Draves | Image credit: International Powerlifting Federation) With her landmark victory, Draves now sets her sights on senior international competitions. 'It was an exciting journey. I'm happy I could do it,' she said. 'I could kind of be a different force in powerlifting being a young woman that could do well.' After graduating, Draves told CTV News she plans to return to Canada and explore the country's powerlifting scene. 'It is a bit addictive,' she said with a chuckle, acknowledging her drive to push herself further.
Yahoo
5 days ago
- Business
- Yahoo
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended June 30, 2025, and provided business updates. "The recently received full data set from our CORAL trial for chronic cough in patients with IPF bolsters the statistically-significant topline results presented in June. This data marks a major milestone for Trevi as it shows consistency and clinically meaningful benefit for these patients," said Jennifer Good, President and CEO of Trevi Therapeutics. "Chronic cough is a debilitating and underserved condition for patients with IPF, and these results, along with the positive RCC data from our RIVER trial announced earlier this year, reinforce our belief in Haduvio's potential to transform care of chronic cough and the lives of these patients. We expect our current cash and investments to provide us with cash runway into 2029, giving us the financial strength to advance Haduvio through late-stage development and several key clinical milestones, as well as enabling pre-commercial planning activities." Second Quarter 2025 Financial Results and Recent Business Highlights Positive topline results from the Phase 2b CORAL trial evaluating Haduvio for the treatment of chronic cough in patients with IPF (N=165) were announced in June 2025. Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups. The 108 mg BID, 54 mg BID, and 27 mg BID dose groups achieved statistically-significant reductions from Baseline of 60.2% (p<0.0001), 53.4% (p<0.0001), and 47.9% (p<0.01), respectively, compared to a placebo reduction from Baseline of 16.9%.1 The Company plans to request an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2025 to align on the Phase 3 program. The Company is preparing to initiate the Phase 3 program in the first half of 2026. Additional analyses from the Phase 2b CORAL trial showed positive results with Haduvio on the Leicester Cough Questionnaire (LCQ) Total Score for the 108 mg BID and 54 mg BID dose groups, increasing the LCQ score by 3.4 points (p=0.01) and 3.7 points (p=0.01), respectively. A 1.3-point increase from Baseline is considered clinically meaningful. The LCQ is considered an important measure of quality of life for patients suffering from chronic cough. Completed a $115 million underwritten offering in June 2025, enabling continued advancement of Haduvio's clinical programs. The Company ended the second quarter of 2025 with $203.9 million in cash, cash equivalents and marketable securities, with expected cash runway into 2029. Second Quarter 2025 Financial HighlightsResearch and development (R&D) expenses: R&D expenses for the second quarter of 2025 decreased to $9.4 million from $10.0 million in the same period in 2024, primarily due to decreased clinical development expenses for the Company's Phase 2a RIVER trial, Human Abuse Potential (HAP) study, and Phase 2b CORAL trial, all of which were actively enrolling patients in the prior year period. These decreases were partially offset by increased costs for the Company's recently initiated Phase 1 drug-drug interaction study, and personnel and related expenses. General and administrative (G&A) expenses: G&A expenses for the second quarter of 2025 increased to $4.3 million from $3.3 million in the same period in 2024, primarily due to an increase in professional fees, and personnel and related expenses. Other Income, net: Other Income, net for the second quarter of 2025 increased to $1.4 million from $0.9 million in the same period in 2024, primarily due to an increase in interest income from higher invested cash equivalent and marketable securities balances. Net loss: For the second quarter of 2025, the Company reported a net loss of $12.3 million compared to the net loss of $12.4 million in the same period in 2024. Conference Call/Webcast To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at An archived replay of the webcast will also be available for 30 days on the Company's website following the event. Upcoming Meetings The Company plans to participate in the following events: August 11-13: Stifel's 2025 Biotech Summer Summit September 3-5: Wells Fargo 2025 Healthcare Conference September 3-5: Cantor Global Healthcare Conference 2025 September 8-10: H.C. Wainwright & Co. 27th Annual Global Investment Conference September 8-10: Morgan Stanley 23rd Annual Global Healthcare Conference September 17-19: 2025 Leerink Partners Biopharma Summit September 27-October 1: European Respiratory Society (ERS) Congress About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in chronic cough patients with IPF and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data, expectations regarding Trevi's uses and sufficiency of capital, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Trevi Therapeutics, Inc. Selected Balance Sheet Data (unaudited) (amounts in thousands)June 30,2025 December 31,2024Cash and cash equivalents$ 117,058 $ 34,097Marketable securities 86,82773,525Working capital 197,98798,919Total assets 208,339110,900Stockholders' equity 198,49399,644 Trevi Therapeutics, Inc. Selected Statement of Operations Data (unaudited) (amounts in thousands, except per share amounts)Three Months EndedJune 30, Six Months EndedJune 30,2025 2024 2025 2024Operating expenses: Research and development$ 9,389 $ 10,021 $ 17,200 $ 18,825General and administrative 4,3333,2687,9926,370Total operating expenses 13,72213,28925,19225,195Loss from operations (13,722)(13,289)(25,192)(25,195)Other income, net 1,4009292,5191,925Loss before income taxes (12,322)(12,360)(22,673)(23,270)Income tax benefit 2183216Net loss$ (12,301) $ (12,352) $ (22,641) $ (23,254)Basic and diluted net loss per common share outstanding$ (0.09) $ (0.12) $ (0.18) $ (0.23)Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 130,350,391101,041,573124,015,763100,279,393 Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286 carlsonj@ Media Contact Rosalia Scampoli 914-815-1465 rscampoli@ 1 One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat (mITT) population. Inclusion of the patient in the placebo group would have resulted in an increased cough frequency from Baseline in the placebo group and much greater placebo-adjusted differences. View original content to download multimedia: SOURCE Trevi Therapeutics, Inc.
Time of India
6 days ago
- Politics
- Time of India
Ethnic groups take out rally, renew demand for bifurcation of Dima Hasao district
1 2 3 4 5 6 Silchar: Tensions have resurfaced in Assam's hill district of Dima Hasao after hundreds of protesters from non-Dimasa tribal communities took out a massive rally in Haflong on Wednesday, renewing their longstanding demand for the bifurcation of the district. R epresentatives of ethnic groups including the Hmar, Zeme Naga, Karbi, Beite, Bhaipe, Rangkhal, Kuki, Khasi, and Jaintia marched through the streets of the district headquarters, holding placards and chanting slogans in support of a separate district for non-Dimasa communities. The rally concluded with a gathering outside the office of the deputy commissioner, where community leaders addressed the crowd. Organised by the Indigenous People's Forum (IPF) along with its sister bodies — the Indigenous Students' Forum (ISF) and the Indigenous Women's Forum (IWF) — the protesters submitted a memorandum to the deputy commissioner, with demands addressed to Assam governor Gulab Chand Kataria and chief minister Himanta Biswa Sarma. At the heart of their demand is the renaming of the district from North Cachar Hills to Dima Hasao in 2010, which they claim is exclusionary and fails to reflect the region's demographic diversity. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo "We have no objection to a separate district for the Dimasas. Let the Dimasa-majority Maibang sub-division be called Dima Hasao. But we want the Haflong sub-division, which comprises other indigenous tribes, to retain the original name — North Cachar Hills," said an IPF spokesperson. He added that non-Dimasa communities constitute nearly 57% of the district's population and should not be identified under a nomenclature that translates to "land of the Dimasa". The demand, which has simmered since the 2010 renaming decision, has seen recurring agitations over the past decade, including bandhs, rail blockades, and rallies. "We will continue our agitation until the district is bifurcated," the spokesperson said. Meanwhile, the Dimasa community — the single largest ethnic group in the region — remains firmly opposed to any move toward division. Dimasa leaders argue that bifurcation would fragment the region and hinder its development. Observers warn that unless the demand for administrative bifurcation is addressed, the district — once scarred by insurgency and ethnic unrest — may again face renewed tensions.
Business Wire
05-08-2025
- Business
- Business Wire
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical development milestones. Key Clinical Development Milestones The Company expects to report topline data from its ongoing PIPE-307 Phase 2 VISTA relapsing-remitting multiple sclerosis (RRMS) trial in the fourth quarter of 2025. This randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial is evaluating safety and efficacy in RRMS patients including clinical and imaging endpoints sensitive to remyelination. More information on this trial can be found at (NCT06083753). Contineum expects to report topline data from its PIPE-791 Phase 1b Positron Emission Tomography (PET) trial in the third quarter of 2025. This open-label, single-center trial is designed to assess the correlation between pharmacokinetics and lysophosphatidic acid 1 (LPA1) receptor occupancy using PET imaging to help guide dose selection in the next stages of clinical development. More information on this trial can be found at (NCT06683612). The Company is proceeding with activities related to the submission of regulatory applications with foreign regulatory authorities, and with the U.S. Food & Drug Administration (FDA), in support of its planned global PIPE-791 Phase 2 proof-of-concept clinical trial in IPF. This trial is expected to be initiated in the fourth quarter of 2025. In order to focus internal clinical resources on the PIPE-791 IPF program, the Company has postponed the initiation of its planned PIPE-791 Phase 2 clinical trial in progressive multiple sclerosis (PrMS) and the advancement of CTX-343 to first-in-human studies. The Company anticipates reporting topline data from its exploratory PIPE-791 Phase 1b trial in patients with chronic pain in the first half of 2026. This randomized, double-blind, placebo-controlled, crossover trial initiated patient dosing in March 2025. PIPE-791 is being evaluated for the treatment of patients with chronic osteoarthritis pain and chronic lower back pain. More information on this trial can be found at (NCT06810245). In December 2024, Johnson & Johnson began recruiting an estimated 124 adult participants for a Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120. This trial is a randomized, double-blind, multicenter, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of PIPE-307/JNJ-89495120 as monotherapy in adult participants with major depressive disorder (MDD). More information on this trial can be found at (NCT06785012). 'We continue to make significant progress with our lead programs and have taken several important steps to focus our key clinical development efforts,' said Carmine Stengone, CEO, Contineum Therapeutics. 'We're focused on initiating a comprehensive, well-designed global Phase 2 proof-of-concept trial in IPF by year-end. In parallel, we elected to postpone the initiation of our planned PIPE-791 PrMS and CTX-343 clinical trials in order to concentrate internal clinical resources on our IPF trial. We also expect to report topline data from our PIPE-307 Phase 2 VISTA trial for the treatment of RRMS in the fourth quarter of 2025. This topline data readout could provide the first evidence of remyelination in this challenging disease setting, while representing a critical step in delivering a novel therapy for patients in need.' Stengone continued, 'With a cash runway that is projected to extend through 2027, our near-term objectives are advancing the PIPE-307 partnered programs and PIPE-791 IPF program through critical milestones.' Second-Quarter 2025 Financial Results Cash, cash equivalents and marketable securities were $175.5 million as of June 30, 2025. Contineum believes it should have sufficient cash resources to fund its planned operations through 2027. During July 2025, the Company generated net proceeds of approximately $8.4 million from the issuance of 2,122,000 shares of Class A common stock in an at-the-market (ATM) offering at a weighted average price of $4.03 per share. Research and development expenses were $14.1 million, a 78 percent increase from the second quarter of 2024, largely due to higher clinical development expenses related to the advancement of the Company's PIPE-791 and PIPE-307 programs and higher employee-related costs. General and administrative expenses were $3.8 million, a 26 percent increase from the second quarter of 2024. The increase was primarily driven by higher stock-based compensation expense and employee-related costs. Net loss was $16.0 million for the three months ended June 30, 2025, as compared to $9.0 million for the prior-year quarter. About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit Forward-Looking Statements Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's clinical trial and product development plans and timelines, including, but not limited to, the Company's expectations related to the regulatory submission process and expected timing of the initiation of the Company's Phase 2 proof-of-concept clinical trial in IPF; the expected timing of topline data from the PIPE-307 Phase 2 VISTA RRMS trial, the PIPE-791 Phase 1b PET trial or from the exploratory Phase 1b chronic pain trial; the Company's cash runway; the indications, anticipated benefits of, and market opportunities for the Company's drug candidates; the Company's business strategies and plans; and the quotations of the Company's management. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control and may cause its actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company's drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the potential for the Company's programs and prospects to be negatively impacted by developments relating to the Company's competitors, including the results of studies or regulatory determinations relating to the Company's competitors; risks associated with reliance on third parties to successfully conduct clinical trials and, in the case of PIPE-307, the Company's reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PIPE-307 for any other indication other than relapsing-remitting multiple sclerosis and, after completion of the Company's PIPE-307 Phase 2 VISTA trial, Janssen Pharmaceutica NV's decision, in its sole discretion, whether or not to further develop PIPE-307 for relapsing-remitting multiple sclerosis; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company's license agreement with Janssen Pharmaceutica NV may not result in the successful development of PIPE-307; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflict may adversely affect the Company's business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company's business, operations and results are included under the captions, 'Risk Factors' and "Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company's website at under the Investor section and on the SEC's website at Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. _____________ (a) Basic and diluted per share amounts are the same for Class A and Class B shares. Expand CONTINEUM THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and par value data) June 30, 2025 Assets Current assets: Cash and cash equivalents $ 20,784 $ 21,943 Marketable securities 154,700 182,817 Prepaid expenses and other current assets 1,355 1,628 Total current assets 176,839 206,388 Property and equipment, net 856 989 Other long-term assets 186 3 Operating lease right-of-use assets 5,007 5,467 Total assets $ 182,888 $ 212,847 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,001 $ 1,811 Accrued expenses 3,747 6,711 Current portion of operating lease liabilities 1,466 1,452 Total current liabilities 7,214 9,974 Operating lease liabilities, net of current portion 4,284 4,807 Total liabilities 11,498 14,781 Commitments and contingencies (Note 8) Stockholders' equity: Class A common stock, $0.001 par value; authorized shares—200,000,000 at June 30, 2025 and December 31, 2024; issued and outstanding shares—19,190,723 and 19,125,377 at June 30, 2025 and December 31, 2024, respectively. 19 19 Class B common stock, $0.001 par value; authorized shares—20,000,000 at June 30, 2025 and December 31, 2024; issued and outstanding shares—6,729,172 at June 30, 2025 and December 31, 2024. 7 7 Preferred stock, $0.001 par value; authorized shares—10,000,000 at June 30, 2025 and December 31, 2024; no shares issued or outstanding at June 30, 2025 and December 31, 2024. — — Additional paid-in-capital 320,649 315,371 Accumulated deficit (149,432 ) (117,402 ) Accumulated other comprehensive income 147 71 Total stockholders' equity 171,390 198,066 Total liabilities and stockholders' equity $ 182,888 $ 212,847 Expand
Time of India
02-08-2025
- Lifestyle
- Time of India
Pushing the padel: Why this tennis-squash hybrid is catching urban imagination
1 2 Gurgaon: The thwack of balls against glass walls echoes through an air-conditioned container-like structure, sitting in the middle of a large spread of empty plot. Inside, players dart across courts, wielding what appears to be a hybrid between a tennis racquet and a table tennis paddle. Forty-love, calls out the referee. The court, in a glass enclosure, resembles squash. What are we watching? This is the world of padel, the latest racquet sport to capture urban imaginations. Delhi-based lawyer Daksha Arora (34) had never played a racquet sport before. But now, she's a regular at Rulo Club in Panchsheel Park. "I play padel thrice a week. Initially, I had started with pickleball, but the sound of the plastic ball irked me. I saw people playing padel in the adjacent court and got hooked to it with time," she says. You Can Also Check: Gurgaon AQI | Weather in Gurgaon | Bank Holidays in Gurgaon | Public Holidays in Gurgaon The tennis-squash hybrid — played on a 20x10m court enclosed by glass walls — is quietly changing the way urban residents approach recreational sports. The game uses a foam and optical fibre racquet with holes instead of strings, making it lighter and more manageable than its tennis counterpart. Players initiate rallies with underhand serves, and the glass walls become part of strategic gameplay — if the ball hits the opposition's glass wall directly, you earn a point. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like TV providers are furious: this gadget gives you access to all channels Techno Mag Learn More Undo But if it bounces off during play, the rally continues. Padel has been around. It originated in Mexico in the last 60s and became Spain's second-most popular sport after soccer. Its journey in India began only a decade ago. But over the last 12 months, padel's popularity has been witnessing a surge. "Today, there are 40 padel courts in Delhi-NCR. In the last three months alone, we added 18 courts," says Suhail Narain, founder of Hudle, which facilitates court bookings. Gurgaon, with its indoor courts, has many padel enthusiasts sweating it out, providing a recreation sport alternative to tennis, badminton and pickleball, guaranteeing good cardio and a workout for those muscles. Padel Rushh, located in Sector 65, has air-cooled courts and coaching programmes. "We see a balanced mix — around 40% beginners, 40% intermediate, and 20% advanced players," says Mrigya Sharma, co-founder of the club. The club's efforts have not gone unnoticed. Headed by Darpan Vasudev, Padel Rushh represented India in the Euro Padel League for the first time this year. The club also hosts in-house tournaments and participates in intercity league exchanges, further cementing its role in the sport's growth. The Indian Padel Federation (IPF) has been instrumental in promoting the sport across the country. Ronnie Sehgal, general secretary of IPF, traces the sport's roots in India to a tennis exchange programme. Sneha Abraham Sehgal, president of IPF, discovered padel in Spain and was determined to introduce it to India, leading to the installation of the first padel court in Bengaluru in 2016. But it was the pandemic-induced lockdown that proved to be a turning point for padel in the country. While most sports were restricted in the UAE, padel thrived. This led to a surge in interest among Indians living in or visiting Dubai. The enthusiasm gradually spread back home. Today, it's showing in the increase in the number of padel courts in cities. Padel is also attracting corporate interest. Last year, JSW Sports backed Padel Park in a funding round to expand franchise centres. It's Mumbai that currently boasts the most vibrant padel scene, with celebrities like David Beckham, MS Dhoni, Alia Bhatt, and Varun Dhawan adding to the sport's allure in courts there. The sport's growth, however, is not without challenges. Setting up a padel court can be expensive, with costs ranging from Rs 16 lakh to Rs 22 lakh. Nikhil Sachdev, co-founder of Padel Park India, acknowledges the financial barriers, but is optimistic about the sport's potential. "In the last 18 months, we've installed about 150 padel courts across the country," he says. IPF has initiated efforts to make padel more affordable, particularly in Tier 2 cities. "We're working with clubs to encourage more inclusive pricing and community engagement," says Sehgal. The federation, he adds, is also focused on developing international-level coaching to produce advanced players capable of competing on the world stage by 2026. For many, padel is more than just a sport — it's a lifestyle. Karan Singh Chabbra, a brand consultant, sees padel as a social activity that brings people together. "Now, there are padel courts, and there are cafes on the side. So, people come, they sip coffee, they talk, they play a game, they come back and spend the day," he says. Whether it's a fun alternative to cardio or a serious athletic pursuit, padel is carving out a niche for itself — slowly but steadily. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
